300347 泰格医药
已收盘 11-10 15:00:00
资讯
新帖
简况
医药创新的长期主义与 CNS 研发攻坚 ｜泰格医药 CPHI 前沿分享
同花顺 · 18:10
医药创新的长期主义与 CNS 研发攻坚 ｜泰格医药 CPHI 前沿分享
研报掘金丨中邮证券：泰格医药业绩复苏趋势明确，维持“买入”评级
格隆汇 · 15:09
研报掘金丨中邮证券：泰格医药业绩复苏趋势明确，维持“买入”评级
大行评级｜瑞银：泰格医药拟参与方达私有化，或有助聚焦核心业务
格隆汇 · 11:54
大行评级｜瑞银：泰格医药拟参与方达私有化，或有助聚焦核心业务
瑞银：维持泰格医药(03347)“买入”评级及52.6港元目标价 参与方达控股(01521)私有化或有助聚焦核心业务
智通财经 · 11:17
瑞银：维持泰格医药(03347)“买入”评级及52.6港元目标价 参与方达控股(01521)私有化或有助聚焦核心业务
大行评级｜大摩：降泰格医药A股目标价至53元，维持“与大市同步”评级
格隆汇 · 11:14
大行评级｜大摩：降泰格医药A股目标价至53元，维持“与大市同步”评级
港股异动 | 方达控股(01521)复牌涨近50% 泰格医药参与方达控股私有化并剥离海外实验室业务
智通财经 · 09:39
港股异动 | 方达控股(01521)复牌涨近50% 泰格医药参与方达控股私有化并剥离海外实验室业务
智通港股早知道 | 中资券商积极响应SFISF业务 优必选(09880)与中国电信订下十万台机器人合约
智通财经 · 07:23
智通港股早知道 | 中资券商积极响应SFISF业务 优必选(09880)与中国电信订下十万台机器人合约
股市必读：泰格医药新发布《第六届董事会第五次会议决议公告》
证券之星 · 02:59
股市必读：泰格医药新发布《第六届董事会第五次会议决议公告》
泰格医药（300347）披露参与子公司方达控股私有化及出售资产公告，11月09日股价下跌0.66%
证券之星 · 11-09 22:50
泰格医药（300347）披露参与子公司方达控股私有化及出售资产公告，11月09日股价下跌0.66%
A股公告精选 | 发行股份及支付现金收购钰泰半导体 艾为电子(688798.SH)11月10日起停牌
智通财经 · 11-09 20:16
A股公告精选 | 发行股份及支付现金收购钰泰半导体 艾为电子(688798.SH)11月10日起停牌
泰格医药：拟参与子公司方达控股私有化并剥离海外实验室业务
格隆汇 · 11-09 19:18
泰格医药：拟参与子公司方达控股私有化并剥离海外实验室业务
泰格医药：截至2026年10月30日公司累计回购股份2096.35万股
南方财经网 · 11-03
泰格医药：截至2026年10月30日公司累计回购股份2096.35万股
研报掘金｜东吴证券：维持泰格医药“买入”评级，临床CRO龙头盈利修复可期
格隆汇 · 11-03
研报掘金｜东吴证券：维持泰格医药“买入”评级，临床CRO龙头盈利修复可期
泰格医药（300347）10月30日主力资金净买入2241.86万元
证券之星 · 11-02
泰格医药（300347）10月30日主力资金净买入2241.86万元
股市必读：泰格医药三季报 - 第三季度单季净利润同比下降77.85%
证券之星 · 11-02
股市必读：泰格医药三季报 - 第三季度单季净利润同比下降77.85%
泰格医药（300347）2026年三季报简析：增收不增利，公司应收账款体量较大
证券之星 · 10-31
泰格医药（300347）2026年三季报简析：增收不增利，公司应收账款体量较大
图解泰格医药三季报：第三季度单季净利润同比下降77.85%
证券之星 · 10-30
图解泰格医药三季报：第三季度单季净利润同比下降77.85%
泰格医药(03347)开展跨境资金池结算业务
智通财经 · 10-29
泰格医药(03347)开展跨境资金池结算业务
泰格医药(03347)前三季度归母净亏损2.72亿元 同比盈转亏
智通财经 · 10-29
泰格医药(03347)前三季度归母净亏损2.72亿元 同比盈转亏
泰格医药：Q3净利1.41亿元，同比下降77.85%，环比扭亏为盈
格隆汇 · 10-29
泰格医药：Q3净利1.41亿元，同比下降77.85%，环比扭亏为盈
加载更多
公司概况
公司名称：
杭州泰格医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2012-08-17
主营业务：
杭州泰格医药科技股份有限公司的主营业务是临床CRO业务。公司的主要产品是临床试验技术服务、临床试验相关及实验室服务。
发行价格：
37.88
{"stockData":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":51.25,"timestamp":1794294204000,"preClose":51.27,"halted":0,"volume":6023217,"delay":0,"changeRate":-0.0004,"floatShares":560000000,"shares":855000000,"eps":-0.4732,"marketStatus":"已收盘","change":-0.02,"latestTime":"11-10 15:00:00","open":52.15,"high":52.37,"low":50.9,"amount":309000000,"amplitude":0.0287,"askPrice":51.26,"askSize":76,"bidPrice":51.25,"bidSize":69,"shortable":0,"etf":0,"ttmEps":-0.4732,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794360600000},"marketStatusCode":5,"adr":0,"adjPreClose":51.27,"symbolType":"stock","openAndCloseTimeList":[[1794274200000,1794281400000],[1794286800000,1794294000000]],"highLimit":56.4,"lowLimit":46.14,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":855142270,"isCdr":false,"pbRate":2.23,"roa":"--","roe":"--","epsLYR":1.04,"committee":0.288462,"marketValue":43826000000,"turnoverRate":0.0107,"status":1,"hkstockBrief":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":38.94,"timestamp":1794298116006,"preClose":38.84,"halted":0,"volume":761900,"delay":0,"premium":"-35.41"},"floatMarketCap":28717000000},"requestUrl":"/m/hq/s/300347","defaultTab":"news","newsList":[{"id":"2682314395","title":"医药创新的长期主义与 CNS 研发攻坚 ｜泰格医药 CPHI 前沿分享","url":"https://stock-news.laohu8.com/highlight/detail?id=2682314395","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682314395?lang=zh_cn&edition=full","pubTime":"2026-11-10 18:10","pubTimestamp":1794305400,"startTime":"0","endTime":"0","summary":"在创新药行业深度调整的当下，如何守住临床初心、走出可持续的转化之路，成为产业共同追问的命题。在11月5日启幕的CPHI思享会第六届医药创新与临床转化年会上，泰格医药带来两场重磅分享， ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261110/c681669302.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261110/c681669302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1576","BK1141","LU1146622755.USD","159938","LU1820825898.SGD","09939","BK0077","CPHI","300347","BK1515","BK0174","BK1583","BK0216","BK4007","03347","BK0028","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682936933","title":"研报掘金丨中邮证券：泰格医药业绩复苏趋势明确，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2682936933","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682936933?lang=zh_cn&edition=full","pubTime":"2026-11-10 15:09","pubTimestamp":1794294583,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["161027","LU1146622755.USD","LU1820825898.SGD","BK0077","BK0174","300347","BK0028","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682535299","title":"大行评级｜瑞银：泰格医药拟参与方达私有化，或有助聚焦核心业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2682535299","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682535299?lang=zh_cn&edition=full","pubTime":"2026-11-10 11:54","pubTimestamp":1794282891,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK1141","BK1583","BK0077","03347","LU1146622755.USD","300347","LU1820825898.SGD","BK1576","BK0174","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682535452","title":"瑞银：维持泰格医药(03347)“买入”评级及52.6港元目标价 参与方达控股(01521)私有化或有助聚焦核心业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2682535452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682535452?lang=zh_cn&edition=full","pubTime":"2026-11-10 11:17","pubTimestamp":1794280628,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，维持泰格医药“买入”评级及52.6港元目标价。泰格医药宣布将通过全资附属公司香港泰格，参与方达控股私有化及业务分拆。瑞银认为，若交易按计划完成，泰格医药或可取得中国内地非目标业务及约18.1亿元人民币现金，并有权收取Charles River Laboratories支付的额外对价款项，交易或有助泰格医药剥离非核心业务，聚焦临床CRO服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01521","03347","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682532354","title":"大行评级｜大摩：降泰格医药A股目标价至53元，维持“与大市同步”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2682532354","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682532354?lang=zh_cn&edition=full","pubTime":"2026-11-10 11:14","pubTimestamp":1794280456,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300347","02843","BK0216","02846","BK1576","BK1583","LU1820825898.SGD","BK1610","07233","03188","BK1147","LU1146622755.USD","02822","03347","03130","83130","159982","BK0174","BK1141","83188","82823","399300","82822","02827","82843","82846","02823","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682835616","title":"港股异动 | 方达控股(01521)复牌涨近50% 泰格医药参与方达控股私有化并剥离海外实验室业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2682835616","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682835616?lang=zh_cn&edition=full","pubTime":"2026-11-10 09:39","pubTimestamp":1794274742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，方达控股复牌涨近50%，截至发稿，涨39.6%，报2.08港元，成交额1252.88万港元。消息面上，泰格医药公告称，公司拟出售对子公司方达控股的控制权并剥离其海外实验室业务。公司全资子公司香港泰格与CRL、李松博士等共同设立SanRex作为收购主体，以计划安排方式将方达控股私有化。公告称，私有化完成后，方达控股将成为SanRex全资子公司。分拆交易完成后，公司不再持有方达控股股份，仅保留中国境内非目标业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0174","BK0216","BK4585","LU1146622755.USD","BK1583","BK0028","BK1576","300347","VXUS","BK1141","01521","BK0077","KCAI","BK4588","03347","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682301343","title":"智通港股早知道 | 中资券商积极响应SFISF业务 优必选(09880)与中国电信订下十万台机器人合约","url":"https://stock-news.laohu8.com/highlight/detail?id=2682301343","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682301343?lang=zh_cn&edition=full","pubTime":"2026-11-10 07:23","pubTimestamp":1794266631,"startTime":"0","endTime":"0","summary":"优必选与中国电信订下十万台机器人合约11月9日，中国电信全资子公司天翼电信终端与港股“人形机器人第一股”优必选签署全面战略合作协议。截至收盘，暗盘交易显示报价10.06港元，较招股价8.88港元上涨13.29%，每手500股，不计手续费，每手赚590港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","LU0039217434.USD","BK1589","BK1133","BK1166","BK1576","HK0000286598.CNH","HK0000288743.USD","01304","BK1163","BK1610","01138","HK0000352382.USD","300347","BK1583","BK1535","SG9999014674.SGD","00728","BK1506","HK0000352291.HKD","600026","601728","BK1141","688279","BK1183","09880","BK1613","BK1536","HK0000288784.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682785333","title":"股市必读：泰格医药新发布《第六届董事会第五次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682785333","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682785333?lang=zh_cn&edition=full","pubTime":"2026-11-10 02:59","pubTimestamp":1794250756,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第五次会议决议公告杭州泰格医药科技股份有限公司于2026年11月9日召开第六届董事会第五次会议，审议通过《关于参与子公司方达控股私有化及出售资产的议案》，拟通过设立要约人SanRex Limited对控股子公司方达控股实施私有化，并进行分拆交易。本次交易预计对公司最近一个会计年度经审计净利润影响超过50%，需提交公司股东会审议。会议还审议通过提请股东会授权董事会办理相关事宜及召开2026年第四次临时股东会的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000003353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","BK1141","LU1820825898.SGD","BK0077","LU1146622755.USD","BK1576","BK1583","BK0216","03347","BK0174","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682384819","title":"泰格医药（300347）披露参与子公司方达控股私有化及出售资产公告，11月09日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682384819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682384819?lang=zh_cn&edition=full","pubTime":"2026-11-09 22:50","pubTimestamp":1794235855,"startTime":"0","endTime":"0","summary":"截至2026年11月9日收盘，泰格医药报收于51.27元，较前一交易日下跌0.66%，最新总市值为438.43亿元。公告显示，公司拟参与子公司方达控股私有化并出售资产。本次交易包括私有化和分拆交易两部分，通过设立SanRex以计划安排方式将方达控股私有化，后续进行资产重组、股权调整和股权转让。本次交易需经公司股东会、美国HSR反垄断审批、方达控股特别股东大会等批准，存在不确定性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900024685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0028","BK0174","LU1820825898.SGD","LU1146622755.USD","300347","BK1576","01521","03347","BK1141","BK1583","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682004938","title":"A股公告精选 | 发行股份及支付现金收购钰泰半导体 艾为电子(688798.SH)11月10日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2682004938","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682004938?lang=zh_cn&edition=full","pubTime":"2026-11-09 20:16","pubTimestamp":1794226563,"startTime":"0","endTime":"0","summary":"今日聚焦1、艾为电子：拟发行股份及支付现金收购钰泰半导体股权，11月10日起停牌艾为电子公告称，公司正在筹划以发行股份及支付现金的方式购买钰泰半导体股份有限公司股权并募集配套资金，经初步测算可能构成重大资产重组，不会导致实际控制人发生变更，不构成重组上市;因事项尚存在不确定性，公司股票及可转债“艾为转债”自2026年11月10日开市起停牌并暂停转股，预计停牌时间不超过10个交易日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688798","002124","BK0183","BK0077","00874","301302","BK0188","688117","BK0175","BK0214","BK0195","BK0097","BK0231","BK0209","LU1820825898.SGD","300347","BK0012","300892","BK0070","BK0216","03347","LU1146622755.USD","BK0196","BK0096","600332","BK0239","BK0240","BK0028","BK0174"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682170804","title":"泰格医药：拟参与子公司方达控股私有化并剥离海外实验室业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2682170804","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682170804?lang=zh_cn&edition=full","pubTime":"2026-11-09 19:18","pubTimestamp":1794223092,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0174","BK1576","LU1146622755.USD","300347","BK1141","03347","LU1820825898.SGD","BK0077","BK1583","01521","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680787743","title":"泰格医药：截至2026年10月30日公司累计回购股份2096.35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680787743","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680787743?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:21","pubTimestamp":1793694060,"startTime":"0","endTime":"0","summary":"南财智讯11月3日电，泰格医药公告，截至2026年10月30日，公司通过回购专用证券账户以集中竞价交易方式回购股份2096.35万股，回购股数占公司目前总股本的2.43%，最高成交价为42.78元/股，最低成交价为38.22元/股，已使用资金总额为8.24亿元（不含交易费用）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033920268341.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033920268341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","LU1146622755.USD","BK1141","300347","BK1583","BK1576","BK0028","BK0077","BK0174","03347","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680710548","title":"研报掘金｜东吴证券：维持泰格医药“买入”评级，临床CRO龙头盈利修复可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2680710548","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680710548?lang=zh_cn&edition=full","pubTime":"2026-11-03 15:27","pubTimestamp":1793690837,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0009","BK0276","BK0183","BK0174","BK0077","LU1820825898.SGD","300347","BK0216","BK0012","LU1146622755.USD","BK0188","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786971","title":"泰格医药（300347）10月30日主力资金净买入2241.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786971?lang=zh_cn&edition=full","pubTime":"2026-11-02 09:05","pubTimestamp":1793581539,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月30日收盘，泰格医药报收于49.67元，上涨3.07%，换手率3.0%，成交量16.83万手，成交额8.44亿元。近5日资金流向一览见下表：泰格医药融资融券信息显示，融资方面，当日融资买入3884.24万元，融资偿还4324.0万元，融资净偿还439.77万元。泰格医药主营业务：临床试验技术服务和临床试验相关服务及实验室服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200003253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1576","BK1583","LU1820825898.SGD","BK0174","BK0077","LU1146622755.USD","BK1141","BK0216","300347","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680620729","title":"股市必读：泰格医药三季报 - 第三季度单季净利润同比下降77.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680620729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680620729?lang=zh_cn&edition=full","pubTime":"2026-11-02 03:24","pubTimestamp":1793561055,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第三季度单季度归母净利润1.41亿元，同比下降77.85%。业绩披露要点财务报告泰格医药2026年三季报显示，前三季度公司主营收入57.92亿元，同比上升15.23%；归母净利润-2.72亿元，同比下降126.66%；扣非净利润4.5亿元，同比上升38.08%；其中2026年第三季度，公司单季度主营收入20.84亿元，同比上升17.38%；单季度归母净利润1.41亿元，同比下降77.85%；单季度扣非净利润1.72亿元，同比上升49.62%；负债率16.88%，投资收益2932.85万元，财务费用6575.23万元，毛利率27.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200000859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679229572","title":"泰格医药（300347）2026年三季报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2679229572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679229572?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:52","pubTimestamp":1793418735,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泰格医药发布2026年三季报。按单季度数据看，第三季度营业总收入20.84亿元，同比上升17.38%，第三季度归母净利润1.41亿元，同比下降77.85%。本报告期泰格医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达160.36%。本次财报公布的各项数据指标表现一般。去年的净利率为11.78%，算上全部成本后，公司产品或服务的附加值一般。本文数据来源于泰格医药2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100025500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1820825898.SGD","03347","BK1583","LU1146622755.USD","BK0077","300347","BK1576","BK0028","BK0216","BK0174","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679928238","title":"图解泰格医药三季报：第三季度单季净利润同比下降77.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679928238","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679928238?lang=zh_cn&edition=full","pubTime":"2026-10-30 02:46","pubTimestamp":1793299613,"startTime":"0","endTime":"0","summary":"证券之星消息，泰格医药2026年三季报显示，前三季度公司主营收入57.92亿元，同比上升15.23%；归母净利润-2.72亿元，同比下降126.66%；扣非净利润4.5亿元，同比上升38.08%；其中2026年第三季度，公司单季度主营收入20.84亿元，同比上升17.38%；单季度归母净利润1.41亿元，同比下降77.85%；单季度扣非净利润1.72亿元，同比上升49.62%；负债率16.88%，投资收益2932.85万元，财务费用6575.23万元，毛利率27.35%。财报数据概要请见下图:本文数据来源于泰格医药2026年三季报，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000005521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679847207","title":"泰格医药(03347)开展跨境资金池结算业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2679847207","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679847207?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:33","pubTimestamp":1793269984,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，为使公司及子公司(含公司直接或间接持股的境内外全资、控股子公司)更高效地统筹境内外资金，进一步支持境外业务拓展，公司拟以泰格医药作为主办企业，在具备国际结算业务能力的银行开展跨境资金池结算业务。通过开展跨境资金池结算业务，公司及纳入资金池的境内外子公司将实现跨境人民币及外币资金的集中管理和统一调度，有效开展资金余缺调剂与归集，提升公司内部资金配置效率。此举有利于降低资金使用成本、提高资金使用效率，同时强化境外资金安全管控，优化整体业务流程，为公司境内外业务的协同发展提供更灵活高效的金融支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","BK1583","03347","BK0216","BK0077","510905","BK1576","BK1141","513105","300347","LU1820825898.SGD","BK0028","BK0174"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679799424","title":"泰格医药(03347)前三季度归母净亏损2.72亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2679799424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679799424?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:38","pubTimestamp":1793266727,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布2026年前三季度业绩，该集团前三季度取得营业收入57.92亿元，同比增长15.23%;归母净亏损2.72亿元，同比盈转亏;每股基本亏损0.32元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK0216","BK0077","300347","BK0174","BK0028","LU1146622755.USD","03347","BK1583","LU1820825898.SGD","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679648475","title":"泰格医药：Q3净利1.41亿元，同比下降77.85%，环比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2679648475","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679648475?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:01","pubTimestamp":1793264516,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300347","BK0174","BK1141","BK0077","LU1146622755.USD","BK0216","BK1576","BK1583","BK0028","03347","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794309633971,"stockEarnings":[{"period":"1week","weight":0.0324},{"period":"1month","weight":-0.0709},{"period":"3month","weight":-0.0625},{"period":"6month","weight":0.0473},{"period":"1year","weight":-0.1184},{"period":"ytd","weight":-0.0932}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0401},{"period":"3month","weight":-0.0695},{"period":"6month","weight":-0.1371},{"period":"1year","weight":-0.0842},{"period":"ytd","weight":-0.0776}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州泰格医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2012-08-17","address":"浙江省杭州市滨江区浦沿街道陆家潭街508号6层601-610室","registeredCapital":"85514万元","survey":" 杭州泰格医药科技股份有限公司的主营业务是临床CRO业务。公司的主要产品是临床试验技术服务、临床试验相关及实验室服务。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,300347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}